• The global generics market is expected to grow at a 6.3% CAGR through 2022
  • The U.S. generics market was at $66 billion in gross sales in 2016
  • $200 billion of brand drug sales are at risk of losing exclusivity between 2017-2022
  • The U.S. “branded generics” market reached $50 billion in 2016 (up 7% vs. 2015)
  • Oral solids represent the largest market segment at about $214 billion in the U.S.
  • Handa’s pipeline is focused on higher-barrier oral solids (modified release and ODT)